Literature DB >> 3157750

The isolation and characterization of the human helper inducer T cell subset.

C Morimoto, N L Letvin, A W Boyd, M Hagan, H M Brown, M M Kornacki, S F Schlossman.   

Abstract

Monoclonal antibody anti-4B4 was produced by fusing NS1 myeloma with spleen cells of a mouse immunized with Saguinus oedipus lymphocyte. This anti-4B4 antibody defines a 135-KD cell surface protein that is widely distributed throughout the hematopoietic system. More importantly, anti-4B4 is reactive with functionally unique human T cell subsets. Anti-4B4 antibody was reactive with approximately 41% of unfractionated T cells, 41% of T4+ inducer cells, and approximately 43% of T8+ cytotoxic/suppressor population. This antibody subdivided peripheral blood T4+ cells into two functionally distinct populations. The T4+4B4+ subset proliferates relatively poorly upon stimulation with Con A and autologous cell antigens (AMLR) but well on exposure to soluble antigens, and it provides a good helper signal for PWM-induced Ig synthesis. The T4+4B4- subset, in contrast, proliferates well to Con A stimulation and autologous cell antigen (AMLR) but relatively poorly to soluble antigen stimulation, and provides little help to B cells for PWM-induced Ig synthesis. The T4+4B4- subset is largely 2H4+ and functions as the inducer of the T8+ suppressor cells. Thus, the present results suggest that one can divide the human T4 population into two major subsets that are phenotypically and functionally distinct, the human helper inducer subset (T4+4B4+/H.I.) and its reciprocal population defined by anti-2H4, the suppressor inducer subset (T4+2H4+/S.I.).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3157750

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  169 in total

1.  Functional hierarchy of simultaneously expressed adhesion receptors: integrin alpha2beta1 but not CD44 mediates MV3 melanoma cell migration and matrix reorganization within three-dimensional hyaluronan-containing collagen matrices.

Authors:  K Maaser; K Wolf; C E Klein; B Niggemann; K S Zänker; E B Bröcker; P Friedl
Journal:  Mol Biol Cell       Date:  1999-10       Impact factor: 4.138

2.  In situ activation of helper T cells in the lung.

Authors:  B Raju; C F Tung; D Cheng; N Yousefzadeh; R Condos; W N Rom; D B Tse
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

3.  Primary and secondary human in vitro T-cell responses to soluble antigens are mediated by subsets bearing different CD45 isoforms.

Authors:  M Plebanski; M Saunders; S S Burtles; S Crowe; D C Hooper
Journal:  Immunology       Date:  1992-01       Impact factor: 7.397

4.  Imbalance of CD4+ lymphocyte subsets in patients with mixed connective tissue disease.

Authors:  H Becker; A Langrock; K Federlin
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

5.  Interleukin 2 inhibitor in synovial fluid.

Authors:  P Emery; K C Gentry; A Kelso; I R Mackay
Journal:  Clin Exp Immunol       Date:  1988-04       Impact factor: 4.330

Review 6.  Role of endothelium in chronic inflammation.

Authors:  M Ziff
Journal:  Springer Semin Immunopathol       Date:  1989

7.  Dual expression of CD45RA and CD45RO isoforms on myelin basic protein-specific CD4+ T-cell lines in multiple sclerosis.

Authors:  Y Qin; S Van Den Noort; J Kurt; S Gupta
Journal:  J Clin Immunol       Date:  1993-03       Impact factor: 8.317

8.  Imbalance of CD4+CD29+ and CD4+CD45RA+ T-helper cell subsets in peripheral blood of patients with severe atopic dermatitis.

Authors:  K Jung; A Bittrich; V Klimmek; H Schubert
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

9.  Expression of CD5 and CD72 on T and B cell subsets in rheumatoid arthritis and Sjögren's syndrome.

Authors:  C Jamin; A Lamour; Y L Pennec; M Hirn; P Le Goff; P Youinou
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

10.  Co-expression of the CD45RA and CD45RO antigens on T lymphocytes in chronic arthritis.

Authors:  K L Summers; J L O'Donnell; D N Hart
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.